Senior Editor, Nature Biotechnology, .
Nat Biotechnol. 2020 Nov;38(11):1242-1252. doi: 10.1038/s41587-020-0732-8.
With the first readouts of trials of antibodies against COVID-19 appearing and others coming thick and fast, asked a group of experts to comment on the challenges and timelines for these products.
随着针对 COVID-19 的抗体试验的首批结果出炉,其他试验也陆续公布,我们请专家组对这些产品的挑战和时间线进行了点评。